Background Multidrug-resistant tuberculosis threatens to reverse recent reductions in global tuberculosis incidence. Although children younger than 15 years constitute more than 25% of the worldwide population, the global incidence of multidrug-resistant tuberculosis disease in children has never been quantifi ed. We aimed to estimate the regional and global annual incidence of multidrug-resistant tuberculosis in children.
Introduction
Multidrug-resistant tuberculosis is tuberculosis disease caused by strains of Mycobacterium tuberculosis that are resistant to isoniazid and rifampicin, the backbone of the present fi rst-line treatment regimen. 1 The emergence of M tuberculosis strains resistant to fi rst-line and secondline drugs, [2] [3] [4] [5] and the restricted access to second-line drugs for appropriate treatment, have driven calls for urgent action. [6] [7] [8] [9] Reliable estimates of the incidence of multidrug-resistant tuberculosis are essential to quantify existing gaps in diagnosis and treatment and to garner the resources necessary to prevent morbidity and mortality from the disease. Although it is challenging to estimate the incidence of drug-resistant tuberculosis because of restricted access to drug-susceptibility testing, 10 data emerging from recent drug-resistance surveys and surveillance have suggested that the global incidence of multidrug-resistant tuberculosis exceeds half a million new cases every year. 1 Despite children younger than 15 years constituting more than a quarter of the global population and 40% of the population of low-income countries, 11 the incidence of multidrug-resistant tuberculosis in children has never been estimated.
Bacteriological confi rmation of drug-resistant tuberculosis disease is more diffi cult to attain in children than in adults. Young children are more likely to have paucibacillary and extrapulmonary disease, and cannot expectorate sputum. 12, 13 As a result, a high proportion of child tuberculosis cases are diagnosed on the basis of clinical criteria without microbiological confi rmation. This absence of microbiological confi rmation restricts both the ability to directly measure the incidence of tuberculosis in children 12 and to routinely assess the risk of multidrugresistant tuberculosis among these cases. 14 This challenge notwithstanding, estimates of the incidence of multidrugresistant tuberculosis disease in children are needed to understand the scale of this problem and to ensure that treatment is available, including child-friendly formulations of essential tuberculosis drugs. We aim to estimate the regional and global incidence of multidrugresistant tuberculosis disease in children.
Methods

Study design
We estimated incidence of multidrug-resistant tuberculosis in children using a three-step approach. First, we did a systematic literature review to estimate the risk of multidrug-resistant tuberculosis among child cases of tuberculosis, which we defi ne as the probability of multidrug-resistant tuberculosis conditional on having tuberculosis disease. We estimated this risk by identifying the setting-specifi c relation between the multidrugresistant tuberculosis risk among child tuberculosis cases and among treatment-naive adult tuberculosis cases. Resistance in these two groups is expected to show primary transmission of resistant strains, rather than resistance acquired during previous treatment. We included only treatment-naive adult cases because resistance in previously treated adults represents a mix of acquired and transmitted resistance. We used these reports to quantify the relation between the risk of multidrug-resistant tuberculosis among treatment-naive adults and children. Second, we estimated the incidence of child tuberculosis for each country, adjusting agespecifi c notifi cation data by the age-specifi c risk of smearpositive disease and relating the estimated proportion of tuberculosis cases occurring among children to the national tuberculosis incidence per 100 000 population. Finally, we multiplied our estimates of multidrugresistant tuberculosis risk in cases of child tuberculosis and incidence of child tuberculosis to produce regional estimates of incidence of child multidrug-resistant tuberculosis.
Search strategy and selection criteria
We systematically searched PubMed, Embase, and LILACS electronic databases for primary articles and reviews published up to Jan 12, 2012. The search terms used controlled vocabulary and free text, and included combinations intended to capture reports of drugresistant tuberculosis (eg, "resist*" and "tuberculosis", "drug-resistant tuberculosis") in children (eg, "infan*", "adolescen*", and "child*"). We contacted authors for additional information if the report met all of the following criteria: the drug-susceptibility testing results were not disaggregated by age group (0-14 and ≥15 years), published since 2000, and published in English or Spanish. We also reviewed the reference lists of primary articles and reviews for additional references and searched the regional WHO databases for the Western Pacifi c, African, South-East Asia, and Eastern Mediterranean regions. We compiled an initial database from the electronic searches and removed duplicate citations. Two reviewers (AWT and MCB or CMY) screened these citations by reviewing the title and abstract. Studies were eligible for inclusion if they reported the proportion of children with cultureconfi rmed tuberculosis disease who had isolates tested for susceptibility to both isoniazid and rifampicin.
The appendix shows the complete search strategy, including detailed inclusion and exclusion criteria. We aimed to identify studies reporting the number of children with an isolate showing resistance to both isoniazid and rifampicin (multidrug-resistant tuberculosis) on drug-susceptibility testing as a proportion of all culture-confi rmed cases of child tuberculosis that received suffi cient drug-susceptibility testing to diagnose multidrug-resistant tuberculosis. This measure provides an estimate of risk of multidrug-resistant tuberculosis among child tuberculosis cases. We reviewed all published studies that reported this measure in a patient population that we expected would be representative of risk of multidrug-resistant tuberculosis among cases of child tuberculosis in the study base. Accordingly, we excluded reports in which the inclusion of patients could have been related to drug resistance (eg, clinical trials, case-control studies, targeted testing). We also specifi cally excluded reports from outbreak or contact investigations, in which risk of resistant disease is expected to be highly correlated and less likely to represent risk in the study base of all children with tuberculosis disease. We did not restrict the language of the publications reviewed.
Data extraction
Two reviewers (CMY, AWT) extracted all study data. A third reviewer (JBP) arbitrated any discrepancies between the fi rst two reviewers. All fi nal data were double-entered into a relational database designed in Microsoft Access 2010.
For each study, we extracted data about the number of children with tuberculosis disease who received drugsusceptibility testing for isoniazid and rifampicin, and the proportion of those with isolates resistant to both isoniazid and rifampicin (multidrug-resistant tuberculosis). Where possible, we also extracted the same information for adults. Additional data extracted included location and enrolment years of each study.
For each study that met inclusion criteria, we report the number of children with tuberculosis disease who had isolates tested for multidrug-resistant tuberculosis, and the proportion of those positive for multidrugresistant tuberculosis.
Statistical analysis
Using included studies for which we were able to extract the proportion of multidrug-resistant tuberculosis cases for both children and treatment-naive adults, we estimated the relation between the risk of multidrug-resistant tuberculosis in these two groups. We constructed a linear regression model with the proportion of child tuberculosis cases with multidrug-resistant tuberculosis as the dependent variable and the proportion of treatment-naive adult tuberculosis cases with multidrug-resistant tuberculosis as the explanatory variable. We weighted the regression by the number of child cases in each study that were tested for multidrug-resistant tuberculosis. Because there were several studies based in some countries, we included a random eff ect for country to ensure the variance around the parameter estimate was not inappropriately small because of absence of independence between studies. This parameter estimate thus quantifi ed the relation between the proportion of treatment-naive adult incident tuberculosis cases with multidrug-resistant disease and the proportion of incident child tuberculosis cases with multidrug-resistant disease.
We applied this relation to the 2008 countrywide estimates of the proportion of treatment-naive adult incident tuberculosis cases with multidrug-resistant disease from WHO 15 to obtain country-level estimates of the proportion of incident child tuberculosis cases with multidrug-resistant disease.
Notifi cation data under-report the incidence of tuberculosis disease in children. 12 To correct for this under-reporting, we adjusted smear-positive notifi cations by a factor refl ecting the expected proportion of cases that are smear-positive to estimate the total number of tuberculosis cases. We assumed that the proportion of incident new tuberculosis cases that are smear-positive varied by age (consistent with data and the approach of Murray and colleagues; 16 appendix). For each age group and for all countries reporting at least one child tuberculosis case, we used the mean of two previously reported proportions of age-specifi c risk of smearpositivity 16, 17 to estimate the age-specifi c and countryspecifi c total number of new tuberculosis cases. Because data for previously treated cases are not reported to WHO by age group, we assumed that all previously treated cases were in patients older than 15 years and adjusted
Reports Children
Total child patients with drug-susceptibility testing results for at least isoniazid and rifampicin the notifi cation data by the mean of the proportions of smear-positivity risk for all age groups older than 15 years from the aforementioned studies. 16, 17 We divided the estimated number of new child tuberculosis cases by the total estimated number of tuberculosis cases (new and previously treated) to estimate the country-specifi c proportion of cases occurring in children. We used data from the 151 countries or territories that provided smearpositive notifi cation data (age-disaggregated for new cases) and reported at least one child case of smearpositive tuberculosis.
Because some countries did not report agedisaggregated case notifi cations to WHO, we fi tted a logistic regression with the estimated proportion of tuberculosis cases occurring in children (estimated as described above) as the dependent variable and the log (base 10) of the estimated tuberculosis incidence per 100 000 population as the explanatory variable. This relation between expected proportion of all tuberculosis cases that occur in children and overall tuberculosis incidence was fi rst described by Peter Donald 18 in 2002. Estimation of regression coeffi cients allowed us to estimate the proportion of tuberculosis cases occurring in children for all countries. We then multiplied these proportions by the total estimated tuberculosis incidence per 100 000 in each country in 2010 1 and by the population in each country 19 to obtain the country-specifi c estimated number of child tuberculosis cases.
Finally, to estimate the incidence of child multidrugresistant tuberculosis, we multiplied our estimates of the country-specifi c risk of multidrug-resistant tuberculosis among child tuberculosis cases by the country-specifi c number of child tuberculosis cases. We summed these country-specifi c multidrug-resistant tuberculosis incidences to provide a total estimate of child multidrug-resistant tuberculosis incidence by WHO regional groupings and worldwide in 2010. We used simulation methods to generate 95% CIs around both the child tuberculosis and multidrug-resistant tuberculosis incidence estimates (appendix). We did sensitivity analyses to assess whether our estimation method was likely to introduce bias (appendix).
Role of the funding source
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The lead author and senior authors had access to all the data and were responsible for the decision to submit the manuscript for peer review.
Results
Of 3403 abstracts, we identifi ed 97 studies that were eligible for inclusion in the systematic review (fi gure 1). Data extraction for 35 of these 97 studies relied on additional information provided by authors.
The 97 included studies evaluated 8382 children with tuberculosis who had drug-susceptibility testing, of whom 348 (4%) had multidrug-resistant tuberculosis. Studies were classifi ed according to their setting, data source, restrictions on study population, and type of laboratory where drug-susceptibility testing was done (table 1) . Appendix shows the detailed study characteristics and results, with full references. The appendix also shows the timeline, catchment areas, and data quality of included studies.
Results of drug-susceptibility testing for both treatmentnaive adults and children were extracted from 31 (32%) of the 97 included reports. Studies that included adults but did not provide a breakdown by treatment history accounted for a further 28 (29%) reports. In 38 (39%) reports, drug-susceptibility testing data for children only could be extracted.
From studies for which suffi cient data were available, we estimated that the relation between the proportion of incident child tuberculosis cases with multidrugresistant disease (Y) and the proportion of incident treatment-naive adult tuberculosis cases with multidrugresistant disease (X) was Y=-0·00261+1·0691X (95% CI for the X coeffi cient 0·53-1·61). Figure 2 shows the relation between the proportion of incident treatmentnaive adult tuberculosis cases with multidrug-resistant Each circle represents a study that provided data for the proportion in both adults and children. The size of the circle is proportional to the number of children in the study who had drug-susceptibility testing suffi cient to diagnose multidrug-resistant tuberculosis. The solid line shows the fi tted linear relation as predicted by our linear regression (which was weighted by the number of children in each study who had drug-susceptibility testing suffi cient to diagnose multidrug-resistant tuberculosis). The equation shown represents the fi tted linear regression with y equal to the proportion of child tuberculosis cases with multidrug-resistant tuberculosis and x equal to the proportion of adult tuberculosis cases with multidrug-resistant tuberculosis. Note that one study is excluded from the graph for visualisation purposes (this study included only one child with drug-susceptibility testing and that child had multidrug-resistant tuberculosis resulting in a proportion of 1-off the scale of our graph). The inset shows the portion of the main plot that lies nearest to the X-Y intercept to show those datapoints more clearly. Note that, although the sizes of the datapoints in the inset are proportional to the number of children that received drug-susceptibility testing in those studies, they are proportional relative to the other datapoints in the inset only and are not on the same scale as those in the main plot. disease and the proportion of incident child tuberculosis cases with multidrug-resistant disease in the 31 studies that reported both proportions. In a sensitivity analysis that excluded the two outlying points with proportion of treatment-naive adult cases of multidrug-resistant tuberculosis of roughly 0·2 (fi gure 2), we found similar results (estimated regression line 0·000093+0·9514X). Figure 3 shows the relation between the proportion of tuberculosis cases in children (0-14 years) and the log (base 10) of the estimated tuberculosis incidence per 100 000 by country or territory. Table 2 summarises the regional and worldwide estimates of the incidence of child tuberculosis and multidrug-resistant tuberculosis in 2010. We estimated that there were 999 792 (95% CI 937 877-1 055 414) incident child tuberculosis cases in 2010. Globally, we estimated that 31 948 (95% CI 25 594-38 663) children developed multidrug-resistant tuberculosis disease in 2010.
40% (397 040) of estimated child tuberculosis cases were in the WHO South-East Asia region, 28% (279 825) in the WHO African region, and 18% (179 515) in the WHO Western Pacifi c region. The largest regional incidence of multidrug-resistant tuberculosis in children was in the WHO South-East Asia region, where around 10 000 children (a third of global estimated cases) were estimated to have developed multidrug-resistant tuberculosis disease in 2010. In the same year, the WHO Western Pacifi c region is estimated to have had more than 8000 child cases of multidrug-resistant tuberculosis (more than a quarter of global estimated cases), the WHO European region more than 5000 cases, and the WHO African region more than 4000 cases.
Sensitivity analyses showed that our estimation method did not introduce substantial bias (appendix).
Discussion
Our estimate of multidrug-resistant tuberculosis incidence in children provides an initial assessment of the vast unmet need for diagnosis and treatment annually (panel). Notably, our estimate of total incident child cases of all forms of tuberculosis is twice that estimated by WHO for 2011 and three times the number of child tuberculosis cases notifi ed globally every year. 20 However, no other estimates of multidrug-resistant tuberculosis incidence exist specifi cally for children. A recent systematic review of treatment outcomes in paediatric multidrug-resistant tuberculosis identifi ed reports spanning the past decade with only 315 children treated for multidrug-resistant tuberculosis, 14 whereas the systematic review of 40 years of literature that we report here only identifi ed another 348 children with confi rmed multidrug-resistant tuberculosis. Thus, the total cases of child multidrugresistant tuberculosis that have ever been reported in the literature is only 2% of those that we estimate occurred globally in 2010.
Several factors might explain the sizeable underestimate of the incidence of tuberculosis disease in children. A key factor is that incidence estimates often have as their starting point the number of child tuberculosis cases reported to a government tuberculosis agency. Yet in most countries, these reported cases represent only the tip of the iceberg of child tuberculosis cases; children are 14 years) and the log (base 10) estimated tuberculosis incidence per 100 000 by country or territory Each point represents country or territory-specifi c data. The log (base 10) estimated tuberculosis incidence per 100 000 was as estimated by WHO for 2010. The percentage of tuberculosis cases in children was estimated as described in the methods using smear-positive reported incidence by age reported to WHO for 2010. These estimations were scaled up with data from previous studies to estimate the total tuberculosis incidence (smearpositive and negative) in each age group, and thus the percentage of cases that were in children. When fi tting a regression line to these data, we used simulation methods that incorporated the errors in the estimated percentage of tuberculosis cases in children and the tuberculosis incidence. Therefore, we generated 1000 regression lines to capture the errors in these input data (see methods for further details). The middle shaded area shows the region covered by the median values of the predictions from the 1000 fi tted regression lines of the relation between the percentage of tuberculosis cases in children and the log (base 10) estimated tuberculosis incidence per 100 000. The upper and lower blue shaded areas show the equivalent areas covered by the upper and lower 95% confi dence limits (respectively) for the predicted values of the percentage of tuberculosis cases in children. more likely than adults to have paucibacillary disease and young children (<5 years old) cannot expectorate sputum, preventing microbiological diagnosis. Young children have the highest risks of severe disease and death once infected, but are the least likely to be confi rmed bacteriologically as tuberculosis cases. Furthermore, all available microbiological tests have very low sensitivity for child tuberculosis disease: under programme conditions, the sensitivity of sputum smear microscopy and of sputum cultures is less than 5% and 15%, respectively. In most of the world, however, tuberculosis diagnosis relies heavily on smear microscopy, and most or all reported child tuberculosis cases are smear-positive, underlining the vast gap between true incidence and reported cases.
Estimated number of child tuberculosis cases (95% CI)
The potential reporting gap of child tuberculosis cases is further emphasised by post-mortem examinations and by the yield of intensifi ed case-detection initiatives in private clinics. 21, 22 Irrespective of whether a sick child presents to the private or public sector, clinicians are frequently hamstrung by the dearth of child-friendly formulations of many tuberculosis drugs. 23 Even novel diagnostic tests about which much enthusiasm abounds are unlikely to improve child case detection owing to their very low sensitivity (<15% of those diagnosed by clinical case defi nitions). 24 All these factors together suggest an enormous need to improve the detection of child tuberculosis cases; increased access to care, heightened clinical suspicion of tuberculosis, and more sensitive diagnostic instruments are likely to be needed to address this gap.
Our approach has limitations. First, our quantifi cation of the relation between the multidrug-resistant tuberculosis risk among children with tuberculosis with that of treatment-naive adults with tuberculosis assumes that the relation is generalisable to settings not represented in the systematic review. Despite potential issues with generalisability, it is reassuring that the relation we estimated is consistent with that recently reported by Zignol and colleagues 25 based on surveillance data reported directly to WHO. We also note that 14 (45%) of 31 studies we analysed excluded children with extrapulmonary disease, who constitute a large proportion of the youngest children with tuberculosis disease. However, Zignol and colleagues' 25 analysis found that the risk of multidrugresistant tuberculosis is similar between children younger than 5 years and aged 5-14 years old, suggesting that this limitation might not undermine our estimates.
Second, our approach for estimating tuberculosis incidence in children used age-specifi c, smear-positive tuberculosis notifi cation data reported to the WHO 1 and adjusted these notifi cation data using expected agespecifi c proportions of tuberculosis cases that are smearpositive, from previous studies. 16, 17 The implicit assumption that the results from the previous studies are generalisable to other settings is supported by results from more recent studies from around the world. [26] [27] [28] [29] [30] Our method also assumes that after this adjustment, there are no further age-specifi c diff erences in case detection within one setting. In other words, we expect that even if there is under-reporting, provided it is consistent across age groups, our estimated proportions of tuberculosis cases that occur among children will remain unbiased. We also assume that all children with tuberculosis have never previously been treated for tuberculosis, an assumption that should be robust in most settings. Additionally, we assume that an insignifi cant fraction of tuberculosis cases in children are currently prevented by the treatment of latent infection, because the use of preventive therapy in children has only been used widely in high-resource, lowincidence settings. 31 The relation we estimate between tuberculosis incidence and the fraction of all cases that occur in children was based on that described by Peter Donald 18 using a diff erent set of studies. Our decision to incorporate this relation was based on our understanding of the epidemiology of infectious disease: fi rst, in higher incidence countries, children tend to comprise a larger fraction of the population (in other words, the population pyramids are more triangular in high incidence countries); and second, the fraction of all cases that are child cases is likely to be highest in high incidence settings because the higher force of infection leads to a reduction in the average age of infection. Characterisation of the relation between tuberculosis incidence and the fraction of all cases that
Panel: Research in context
Systematic review
We systematically searched PubMed, Embase, LILACS and WHO regional electronic databases for primary studies and review articles published up to Jan 12, 2012. The search terms used controlled vocabulary and free text and included combinations intended to capture reports of drug-resistant tuberculosis (eg, "resist*" and "tuberculosis", "drugresistant tuberculosis") in children (eg, "infan*", "adolescen*", and "child*"). To identify relevant articles not identifi ed in these primary electronic databases, we also reviewed the reference lists of primary studies and reviews for additional references. Studies were eligible for inclusion if they reported the proportion of children with culture-confi rmed tuberculosis disease who had isolates tested for susceptibility to both isoniazid and rifampicin. We extracted characteristics of included studies which we consider informative about these studies' representativeness of children in the study base. We did not fi nd any studies that attempted to synthesise publications reporting the proportion of children with tuberculosis disease who had multidrug-resistant tuberculosis nor to estimate the global incidence of multidrug-resistant tuberculosis in children. We did not restrict the language of the publications reviewed.
Interpretation
Our study is the fi rst to estimate the global and regional incidences of multidrug-resistant tuberculosis in children. We also produced new estimates of tuberculosis incidence in children that acknowledge the lower smear-positivity rates in children than in adults. These incidence estimates are essential to improve understanding of the gap between the number of children that are identifi ed and treated for tuberculosis and multidrugresistant tuberculosis and the number that need treatment. Only with such understanding can suffi cient resources be allocated to diagnose and treat all children with tuberculosis and avert preventable disability and deaths.
occur in children is dependent on data from a small number of studies. Improved estimates of the incidence of childhood tuberculosis will be possible as more countries report age-disaggregated data and use diagnostic tests that are more sensitive for the detection of tuberculosis disease in children. Further refi nements to incidence estimates will be possible as more and larger studies including children are undertaken.
Our approach also relies on estimates obtained from models developed by WHO 15 -for example, for tuberculosis incidence per 100 000 and for proportions of tuberculosis cases that have multidrug-resistant tuberculosis for which drug resistance surveys had not been done. If these modelled estimates are systematically biased, these errors will be propagated in our estimates of both tuberculosis and multidrug-resistant tuberculosis incidence. Therefore, although our confi dence limits capture the precision of our estimates, if there is any systematic bias present due to these estimated inputs or potentially unmet assumptions, the true numbers of child cases could well fall outside our reported confi dence limits.
We propose that our estimate provides an important starting place for documenting the incidence of multidrugresistant tuberculosis in children and that our method should motivate further discussions on statistical and mathematical techniques that might improve the precision of these estimates. More direct approaches for measurement of multidrug-resistant tuberculosis risk in children and tuberculosis incidence in children will help to reduce uncertainty about multidrug-resistant tuberculosis incidence in children, and, more importantly, will allow the delivery of appropriate treatment. New methods for diagnosing tuberculosis disease and determining drug resistance are becoming available 32 and, if their use can be scaled up to improve routine diagnosis of tuberculosis in children, future estimates of multidrugresistant tuberculosis in children can be based on more robust evidence.
Our estimate of tuberculosis incidence in children is substantially higher than 2011 WHO estimates. 20 We used a diff erent approach from that used by WHO: we explicitly acknowledged that case detection in children is lower than that in adults because of diffi culty in attaining microbiological confi rmation, and on this basis estimated the proportions of all tuberculosis cases that occurred in children. We note that our estimates of child tuberculosis incidence are similar to previously published estimates of roughly 1·3 million cases in 1989 33 and nearly 900 000 cases in 2000. 34 We estimate that each year there is a vast unmet need for treatment of both tuberculosis and multidrug-resistant tuberculosis disease in children, the former previously underestimated and the latter heretofore unknown. Our results point to an urgent need for expanded investment to respond globally to tuberculosis and multidrug-resistant tuberculosis in children, including systematic work to gather more and better empirical data that can be used to estimate disease incidence. Treatment for children with multidrug-resistant tuberculosis is highly eff ective if they can be diagnosed promptly and placed on appropriate drug regimens.
14 Continued failure to detect and treat child cases of tuberculosis and multidrug-resistant tuberculosis will result in the unnecessary deaths of large numbers of children. Improved estimates of the incidence of tuberculosis and multidrug-resistant tuberculosis disease in children-especially in high-incidence countries-will enable improved predictions of the resources that will be needed to fi nd and treat children with tuberculosis and multidrug-resistant tuberculosis successfully.
